Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Ms crawled date : 2022 - 09 - 12 save search
UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT MORGAN STANLEY'S 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE
Published: 2022-09-12 (Crawled : 22:00) - prnewswire.com
UHS | $162.45 -2.39% 270K
|
Health Services
|
| O: -2.19%
H: 0.66%
C: -2.33%
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: -2.37%
H: 0.76%
C: -1.09%
global conference health universal
Driven Brands Announces Secondary Offering of Common Stock
Published: 2022-09-12 (Crawled : 22:00) - prnewswire.com
DRVN | $14.575 -0.51% 310K
|
|
| O: -5.82%
H: 2.47%
C: 1.02%
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: -2.37%
H: 0.76%
C: -1.09%
offering brands
Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board
Published: 2022-09-12 (Crawled : 21:00) - aquestive.com
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: -2.37%
H: 0.76%
C: -1.09%
AQST | $3.815 -3.17% 690K
|
Health Technology
|
| O: -2.08%
H: 2.13%
C: -2.13%
therapeutics
Athene Holding Ltd. Announces Pricing of Tender Offers by Athene Global Funding
Published: 2022-09-12 (Crawled : 20:00) - globenewswire.com
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: -2.37%
H: 0.76%
C: -1.09%
global funding
Sun Country Airlines to Participate in the Morgan Stanley 10th Annual Laguna Conference
Published: 2022-09-12 (Crawled : 18:00) - globenewswire.com
SNCY | $13.84 -2.95% 50K
|
Transportation and Warehousing
|
| O: -0.1%
H: 0.46%
C: -2.47%
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
conference
Haemonetics Earns CE Mark for VASCADE® Vascular Closure Product Portfolio
Published: 2022-09-12 (Crawled : 11:00) - prnewswire.com
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
HAE | $83.95 -1.1% 57K
|
Health Technology
|
| O: 1.47%
H: 1.55%
C: 0.85%
vascade
Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-09-12 (Crawled : 11:00) - globenewswire.com
PHVS | $21.25 5.46% 37K
|
|
| O: -0.16%
H: 4.22%
C: 0.11%
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
financial update results
LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE S | $136.78 -1.17% 48K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $264.99 -0.2% 410K
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras response cancer
John Porter joins Dalma Capital to Lead its Investment Banking Practice from Dubai
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
MS 3 d | $90.27 3.77% 9.2M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE S | $136.78 -1.17% 48K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $264.99 -0.2% 410K
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras lung trial positive cancer
Gainers vs Losers
| 51% | 49% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.